Skip to main content

Table 1 Comparison between critically ill patients with SARS-CoV-2 pneumonia admitted during the first (n = 82) and the second (n = 50) COVID-19 wave

From: Comparison between first and second wave among critically ill COVID-19 patients admitted to a French ICU: no prognostic improvement during the second wave?

 

First wave

n = 82

Second wave

n = 50

p value

Patient’s characteristics and ICU scores

Male sex

66 (81)

38 (76)

0.70

Age, years

62 [55–70]

65 [61–69]

0.20

SAPS II

33 [24–41]

29 [22–37]

0.23

SOFA

4 [3–7]

4 [3–4]

0.07

Main comorbidities

Obesity (body mass index ≥ 30 kg/m2)

37 (46)

22 (44)

0.94

Arterial hypertension

52 (63)

30 (60)

0.84

Diabetes mellitus

35 (43)

22 (44)

1.00

Ischemic cardiopathy

8 (10)

5 (10)

1.00

Cerebro-vascular disease

7 (9)

3 (6)

0.74

Chronic kidney failure

7 (9)

5 (10)

0.77

Chronic respiratory disease

18 (23)

14 (28)

0.62

Immunocompromised status

11 (13)

8 (16)

0.88

Main delays

Days between disease onset and ICU admission

8 [7–12]

10 [8–12]

0.42

 > 7 days between disease onset and ICU admission

50 (64)

37 (74)

0.33

Days between hospital admission and ICU admission

2 [1–4]

3 [1–4]

0.30

Biological data at ICU admission

D-dimers (ng/mL)

2510 [1655–9222]

1665 [1060–3372]

0.04

Prothrombin time (%)

85 [74–96]

90 [83–101]

0.08

Fibrinogen (g/L)

7.6 [6.0–8.7]

7.4 [6.2–8.4]

0.75

Platelets count (G/L)

225 [170–287]

267 [199–344]

0.03

Treatment administered at ICU admission

Glucocorticoidsa

10 (12)

50 (100)

 < 0.001

Intermediate or full-dose thromboprophylaxis

46 (57)

50 (100)

 < 0.001

Antibiotic therapy for bacterial co-infection at ICU admission

18 (22)

14 (29)

0.52

Antiviral drugs (lopinavir-ritonavir or remdesivir)

0 (0)

0 (0)

1.00

Tocilizumab

0 (0)

0 (0)

1.00

Outcome in the ICU

   

Invasive mechanical ventilation (IMV)

72 (88)

32 (64)

0.01

Days between ICU admission and IMV

2 [1–3]

4 [2–5]

 < 0.001

Days between disease onset and IMV

11 [8–13]

14 [11–17]

0.01

Ventilator associated pneumonia

53/72 (74)

24/32 (75)

0.97

Prone positioning

52/72 (72)

30/32 (94)

0.03

Duration of IMV

19 [10–30]

17 [8–31]

0.60

Renal replacement therapy

24 (29)

12 (27)

0.98

Vasopressor support

52 (63)

25 (53)

0.34

Thrombotic events during ICU stay

34 (42)

8 (17)

0.01

Hemorrhagic events during ICU stay

15 (18)

9 (18)

1.00

Length of ICU stay, days

16 [8–30]

14 [9–30]

0.88

Overall ICU mortality

41 (50)

26 (52)

0.96

ICU mortality among patients requiring IMV

41/72 (57)

24/32 (75)

0.13

  1. Continuous variables are reported as median [Interquartile range] and compared between groups using the Student t test. Categorical variables are reported as numbers (percentages) and compared using χ2 test. A p value < 0.05 was considered significant
  2. ICU, Intensive Care Unit; IMV, Invasive Mechanical Ventilation; SAPS2, Simplified Acute Physiology Score; SOFA, Sepsis-related Organ Failure Assessment
  3. aAccording to CAPE COVID [5] (first wave) or RECOVERY [6] (second wave) protocols